How we diagnose Myelodysplastic syndromes

Area of Science:

• Hematology
• Oncology
• Stem Cell Biology

Background:

• Myelodysplastic syndromes (MDS) are clonal myeloid neoplasms of bone marrow stem cells.
• Characterized by ineffective hematopoiesis, dysplasia, peripheral cytopenias (e.g., anemia), and risk of leukemic transformation.
• Diagnosis is suspected based on clinical and lab findings, confirmed by bone marrow examination.

Purpose of the Study:

• To review the current diagnostic approach for patients suspected of Myelodysplastic syndromes (MDS).
• To highlight the essential role of bone marrow examination and cytogenetics in MDS diagnosis and prognosis.
• To discuss the potential future integration of non-invasive technologies in MDS diagnostics.

Main Methods:

• Review of current diagnostic standards for Myelodysplastic syndromes (MDS).
• Emphasis on bone marrow examination, including assessment of dysplasia and blast percentage.
• Inclusion of cytogenetics as a key diagnostic and prognostic tool.

Main Results:

• Bone marrow examination remains the gold standard for MDS diagnosis.
• Cytogenetics is crucial for both diagnosis and prognosis.
• Flow cytometry and genetic characterization are supportive but not mandatory.

Conclusions:

• The current diagnostic pathway for suspected Myelodysplastic syndromes (MDS) relies heavily on invasive bone marrow assessment.
• Cytogenetic analysis is integral to the diagnostic and prognostic workup.
• Advancements in non-invasive technologies, such as peripheral blood genetics, are expected to enhance future MDS diagnostics.